AF
BCAX

Allworth Financial’s Bicara Therapeutics BCAX Stock Holding History

Allworth Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47K Buy
74
+21
+40% +$361 ﹤0.01% 4452
2025
Q4 		$892 Buy
53
+11
+26% +$188 ﹤0.01% 4391
2025
Q3 		$664 Sell
42
-252
-86% -$2.82K ﹤0.01% 4366
2025
Q2 		$2.73K Sell
294
-31
-10% -$369 ﹤0.01% 3570
2025
Q1 		$5.08K Buy
+325
New +$4.32K ﹤0.01% 2750

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Allworth Financial's BCAX Position: Q1 2026 in Review

Allworth Financial increased its Bicara Therapeutics (BCAX) stake by 40% in Q1 2026, buying an estimated $361 and bringing the position to 74 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

Allworth Financial first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.08K in Q1 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Allworth Financial held 74 shares of Bicara Therapeutics worth $1.47K as of Q1 2026.
  • Allworth Financial bought 21 Bicara Therapeutics shares in Q1 2026, an estimated $361.
  • Bicara Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4452 holding.
  • Allworth Financial first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Allworth Financial's Bicara Therapeutics position peaked at $5.08K in Q1 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.